FENDRR reduces tumor invasiveness in prostate cancer PC-3 cells by targeting CSNK1E

Y.-Q. Zhang, X. Chen, C.-L. Fu, W. Zhang, D.-L. Zhang, C. Pang, M. Liu, J.-Y. Wang

Department of Urology Surgery, Beijing Hospital, National Center of Gerontology, Beijing, P.R. China. Yaqun Zhang, MD; e-mail: qtlc15@163.com

---

• Oncology

OBJECTIVE: Prostate cancer, one of the most common malignant tumors in urology, now has become a malignant disease that seriously threatens the health of men in China. Although there are a large number of clinical studies on the treatment of patients with prostate cancer, many patients have entered the advanced stage of diagnosis, and little is known about its pathogenesis.

MATERIALS AND METHODS: We identified a series of ncRNA and TF by differential expression analysis, co-expression analysis, enrichment analysis, connectivity analysis, and hypergeometric test strategies for prostate cancer expression genomes.

RESULTS: 53 modules related to prostate cancer PC-3 cells were obtained, involving module focusing of 4448 genes. Based on these modules, we predicted that miR-26a-5p, miR-130a-3p, miR-519d-3p, etc. have important regulatory effects on prostate cancer PC-3 cells. At the same time, a series of transcription factors (relating to RELA, SOX10, TP53, and TWIST2, etc.) were obtained and may play a key regulatory role in prostate cancer PC-3 cell-related modules.

CONCLUSIONS: These results suggest that FENDRR in prostate cancer may reduce tumor invasion in prostate cancer PC-3 cells by targeting CSNK1E, which may have favourable effort to better understand the underlying pathogenesis of prostate cancer and provide a tough theoretical basis for further studying prostate cancer.

Free PDF Download